Comprehensive cytogenetic analysis of cases referred for suspected chromosomal abnormalities: A Five-year study at Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia, Penang, Malaysia.
Keywords:
Chromosomal abnormalities, cytogenetics, karyotypeAbstract
Chromosomal abnormalities (CA) can affect numerical or structural compositions of chromosomosal DNA leading to a diversity of clinical phenotypic presentations. Awareness of prenatal diagnosis and genetic counselling have improved with advancing medical research but CA remain prevalent as its aetiology is unknown. The objective of this study is to determine the frequencies of various CA in the principle region of north-western Malaysia and compare this data to previous reports to ascertain if statistical differences exist. Karyotype analyses performed at the Genetics Laboratory, Advanced Diagnostic Laboratory (ADL) during the first 5-years of cytogenetic services, totalling 1461 cases, were assessed in this report. Cases suspected of CA were initially diagnosed by clinicians and detailed clinical and family histories were recorded. Peripheral blood lymphocytes of patients were collected and cultured in vitro for acquisition of karyotype by standardized G-banding technique. Fluorescence in situ hybridization (FISH) was conducted in cases suspected of to be DiGeorge, Prader-Willi, Angelman and Williams syndrome. Of the total samples (1805) received and cultured, 1669 (92.46%) successfully yielded results. Abnormal outcomes were observed in 495 cases (29.66%) whereby pronounced majority of cases 299 (68.42%) were Down syndrome. This is followed by Edward, Turner and Patau syndrome, in order of frequency. Numerical CA appears to be prevalent accounting for 85.86% of cases. Structural CA accounted for 14.14% of total positive cases whereby the most common was deletions (34.29%) followed by translocations (20%), ring chromosomes (5.71%), Fragile X syndrome (4.29%), duplications (5.71%) and marker chromosomes (7.14%). The remainder of cases (22.86%) consisted of derivative chromosomes and other complex aberrations. The number of polymorphic variant cases were 27 (1.62%). The number of peripheral blood samples received has significantly increased from 14.3 per month in 2006 to 32.17 per month in 2011. Comparative analysis of our study to previous reports reveal statistical differences in the occurrence of several CA including Edward, Patau, Klinefelter and Fragile-X syndrome. Our experience with peripheral blood samples for cytogenetic analysis demonstrated a success rate of 92.46%. This showed an increase in clinicians validating patients’ diagnoses with karyotyping which is essential in confirming genetic anomalies with the goal to substantiate genetic counselling.References
LG Shaffer, LJ Campbell, ML Slovak (2009). ISCN 2009: An International System for Human Cytogenetic Nomenclature. 1st ed. Karger: Basel; 2009.
RS Verma, H Dosik (1980). Incidence of major chromosomal abnormalities in a referred population for suspected chromosomal aberrations: a report of 357 cases. Clinical Genetics. [Online] 17, pp. 305-308.
WS Choi, KH Kim, YK Paik (1984). A cytogenetic study in patients referred for suspected chromosomal abnormalities. Journal of Hanyang Medical College. [Online] 4, pp. 565-597.
SS Kim, SC Jung, HJ Kim, HR Moon, JS Lee (1999). Chromosome abnormalities in a referred population of suspected chromosomal aberrations: a report of 4117 cases. Journal of Korean Medical Science. [Online] 14, pp. 373-376.
M Balkan, H Akbas, H Isi, D Oral, A Turkyilmaz, S Kalkanli, et al. (2010). Cytogenetic analysis of 4216 patients referred for suspected chromosomal abnormalities in Southeast Turkey. Genetics and Molecular Research. [Online] 9(2), pp. 1094-1103.
SN Heyn, D Perlstein, editors. Down Syndrome [monograph on the internet]. California: eMedicineHealth, WebMD; 2011 [cited 2011 Oct 10]. Available from: http://www.emedicinehealth.com/down_syndrome/article_em.htm/.
EB Hook, JL Hamerton (1977). The frequency of chromosome abnormalities detected in consecutive newborn studies, differences between studies, results by sex and by severity of phenotypic involvement. In: Hook EB, Porter IH, editors. Population cytogenetics: studies in humans. New York: Academic Press; [Online] pp. 63-79.
J Nielsen, M Wohlert (1991). Chromosome abnormalities found among 34910 newborn children: results from a 13-year incidence study in Arhus, Denmark. Human Genetics. [Online] 87, pp. 81-83.
Genetics Home Reference [homepage on the Internet]. Bethesda, MD: Trisomy 13, U.S. National Library of Medicine; c2009-11 [updated 2009 Jan; cited 2011 Oct 10]. Available from: http://ghr.nlm.nih.gov/condition/trisomy-13#definition/.
Genetics Home Reference [homepage on the Internet]. Bethesda, MD: Trisomy 18, U.S. National Library of Medicine; c2009-11 [updated 2009 Jan; cited 2011 Oct 10]. Available from: http://ghr.nlm.nih.gov/condition/trisomy-18#definition/.
Spalding J., Genetics Mosaics Support Group [monograph on the internet]. Laurel, MD: xyTurners; 2004 [cited 2011 Oct 10]. Available from: http://www.xyxo.org/index.html/.
[ National Institute of Child Health & Human Development [homepage on the Internet]. Bethesda, MD: U.S. National Institutes of Health; c2007-11 [updated 2007 May 24; cited 2011 Oct 10]. Available from: http://www.nichd.nih.gov/health/topics/klinefelter_syndrome.cfm/.
Genetics Home Reference [homepage on the Internet]. Bethesda, MD: Turner Syndrome, U.S. National Library of Medicine; c2008-11 [updated 2008 May; cited 2011 Oct 10]. Available from: http://ghr.nlm.nih.gov/condition/turner-syndrome#definition/.
JA Jewell, B Buehler, editors. Fragile X Syndrome [monograph on the internet]. California: Medscape Reference, WebMD; 2011 [cited 2011 Oct 10]. Available from: http://emedicine.medscape.com/article/943776-overview#a0101/.
Genetics Home Reference [homepage on the Internet]. Bethesda, MD: Fragile X Syndrome, U.S. National Library of Medicine; c2007-11 [updated 2007 May; cited 2011 Oct 10]. Available from: http://ghr.nlm.nih.gov/condition/fragile-x-syndrome#definition/.
FI Sahin, Z Yilmaz, OO Yuregir, T Bulakbasi, O Ozer, HB Zeyneloglu (2008). Chromosome heteromorphism an impact on infertility. J Assist Reprod Genet. [Online] 25, pp. 191–195.
AR Brothman, NR Schneider, I Saikevych, LD Cooley, MG Butler, S Patil, et al. (2006). Cytogenetic heteromorphisms: Survey results and reporting practices of Giemsa-band regions that we have pondered for years. Arch Pathol Lab Med. [Online] 130(7), pp. 947–949.
K Yakin, B Balaban, B Urman (2005). Is there a possible correlation between chromosomal variants and spermatogenesis?. International Journal of Urology. [Online] 12, pp. 984-989.
Downloads
Additional Files
Published
Issue
Section
License
JBCS Publication Ethics
JBCS is committed to ensure the publication process follows specific academic ethics. Hence, Authors, Reviewers and Editors are required to conform to standards of ethical guidelines.
Authors
Authors should discuss objectively the significance of research work, technical detail and relevant references to enable others to replicate the experiments. JBCS do not accept fraudulent or inaccurate statements that may constitute towards unethical conduct.
Authors should ensure the originality of their works. In cases where the work and/or words of others have been used, appropriate acknowledgements should be made. JBCS do not accept plagiarism in all forms that constitute towards unethical publishing of an article.
This includes simultaneous submission of the same manuscript to more than one journal. Corresponding author is responsible for the full consensus of all co-authors in approving the final version of the paper and its submission for publication.
Reviewers
Reviewers of JBCS treat manuscripts received for review as confidential documents. Therefore, Reviewers must ensure the confidentiality and should not use privileged information and/or ideas obtained through peer review for personal advantage.
Reviews should be conducted based on academic merit and observations should be formulated clearly with supporting arguments. In cases where selected Reviewer feels unqualified to review a manuscript, Reviewer should notify the editor and excuse himself from the review process in TWO (2) weeks time from the review offer is made.
In any reasonable circumstances, Reviewers should not consider to evaluate manuscripts if they have conflicts of interest (i.e: competitive, collaborative and/or other connections with any of the authors, companies, or institutions affiliated to the papers).
Editors
Editors should evaluate manuscripts exclusively based on their academic merit. JBCS strictly do not allow editors to use unpublished information of authors without the written consent of the author. Editors are required to take appropriate responsive actions if ethical complaints have been presented concerning a submitted manuscript or published paper.
CONFLICT OF INTEREST
Journal of Biomedical and Clinical Sciences requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a ‘competing interests section at the end of the manuscript listing all competing interests (financial and non-financial). Where authors have no competing interests, the statement should read ,The authors have declared that no competing interests exist. Editors may ask for further information relating to competing interests.
Editors and reviewers are also required to declare any competing interests and will be excluded from the peer review process if a competing interest exists. Competing interests may be financial or non-financial. A competing interest exists when the authors interpretation of data or presentation of information may be influenced by their personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment if they were to become public after the publication of the article.
HUMAN AND ANIMAL RIGHTS
All research must have been carried out within an appropriate ethical framework. If there is suspicion that work has not taken place within an appropriate ethical framework, Editors will follow the Misconduct policy and may reject the manuscript, and/or contact the author(s) institution or ethics committee. On rare occasions, if the Editor has serious concerns about the ethics of a study, the manuscript may be rejected on ethical grounds, even if approval from an ethics committee has been obtained.
Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. Further information and documentation to support this should be made available to Editors on request.
Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. The Basel Declaration outlines fundamental principles to adhere to when conducting research in animals and the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines.
A statement detailing compliance with relevant guidelines (e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or ethical approval (including the name of the ethics committee and the reference number where appropriate) must be included in the manuscript. The Editor will take account of animal welfare issues and reserves the right to reject a manuscript, especially if the research involves protocols that are inconsistent with commonly accepted norms of animal research. In rare cases, Editors may contact the ethics committee for further information.
INFORMED CONSENT
For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear in the manuscript, this includes to all manuscripts that include details, images, or videos relating to individual participants.
DATA SHARING POLICY
JBCS strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files, in machine-readable format (such as spreadsheets rather than PDFs) whenever possible
Authors who do not wish to share their data must state that data will not be shared, and give the reason.
COPYRIGHT NOTICE
The JBCS retains the copyright of published manuscripts under the terms of the Copyright Transfer Agreement. However, the journal permits unrestricted use, distribution, and reproduction in any medium, provided permission to reuse, distribute and reproduce is obtained from the Journal's Editor and the original work is properly cited.
While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
Copyright (c) 2023 Journal of Biomedical and Clinical Sciences (JBCS)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
